Advertisement

Neonatale Pharmakologie

  • Ingolf Cascorbi
  • Knud Linnemann
Part of the Molekulare Medizin book series (MOLMED)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

7.7 Literatur

  1. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet:353:717–719PubMedGoogle Scholar
  2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Therap 278:441–446Google Scholar
  3. Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 41:1077–1094PubMedGoogle Scholar
  4. Ang SL, Wierda A, Wong D, Stevens KA, Cascio S, Rossant J, Zaret KS (1993) The formation and maintenance of the definitive endoderm lineage in the mouse: involvement of HNF3/forkhead proteins. Development 119:1301–1315PubMedGoogle Scholar
  5. Asperen van J, Mayer U, Teilingen van O, Beijnen JH (1997) The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86:881–884CrossRefPubMedGoogle Scholar
  6. Ballard PL, Ning Y, Polk D, Ikegami M, Jobe AH (1997) Glucocorticoid regulation of surfactant components in immature lambs. Am J Physiol 273:L1048–L1057PubMedGoogle Scholar
  7. Barrington KJ (2001) The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 1:1CrossRefPubMedGoogle Scholar
  8. Berhane K, Margana RK, Boggaram V (2000) Characterization of rabbit SP-B promoter region responsive to down-regulation by tumor necrosis factor-alpha. Am J Physiol Lung Cell Mol Physiol 279:L806–L814PubMedGoogle Scholar
  9. Bertilsson G, Heidrich J, Svensson K et al (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208–12213CrossRefPubMedGoogle Scholar
  10. Beurton F, Gueret G, Horisberger M, Cheron G, Cresteil T (1999) Transcriptional activation of CYP2C, MxA and Fas in sudden infant death syndrome. Int J Mol Med 3:33–39PubMedGoogle Scholar
  11. Biegel D, Spencer DD, Pachter JS (1995) Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. Brain Res 692:183–189CrossRefPubMedGoogle Scholar
  12. Bolt RJ, van Weissenbruch MM, Lafeber HN, Delemarre-van de Waal HA (2001) Glucocorticoids and lung development in the fetus and preterm infant. Pediatr Pulmonol 32:76–91CrossRefPubMedGoogle Scholar
  13. Bruno MD, Bohinski RJ, Huelsman KM, Whitsett JA, Korthagen TR (1995) Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. J Biol Chem 270:6531–6536PubMedGoogle Scholar
  14. Burchell B, Hume R (1999) Molecular genetic basis of Gilbert’s syndrome. J Gastroenterol Hepatol 14:960–966CrossRefPubMedGoogle Scholar
  15. Carrier O, Pons G, Rey E, Richard MO, Moran C, Badoual J, Olive G (1988) Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther 44:145–151PubMedCrossRefGoogle Scholar
  16. Cetin I (2001) Amino acid interconversions in the fetal-placental unit: the animal model and human studies in vivo. Pediatr Res 49:148–154PubMedGoogle Scholar
  17. Cetin I, Marconi AM, Corbetta C, Lanfranchi A, Baggiani AM, Battaglia FC, Pardi G (1992) Fetal amino acids in normal pregnancies and in pregnancies complicated by intrauterine growth retardation. Early Hum Dev 29:183–186CrossRefPubMedGoogle Scholar
  18. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97–104CrossRefPubMedGoogle Scholar
  19. Chung I, Bresnick E (1995) Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins. Mol Pharmacol 47:677–685PubMedGoogle Scholar
  20. Clark JC, Wert SE, Bachurski CJ, Stahlman MT, Stripp BR, Weaver TE, Whitsett JA (1995) Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA 92:7794–7798PubMedGoogle Scholar
  21. Coceani F, Ackerley C, Seidlitz E, Kelsey L (2001) Function of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the ductus arteriosus from foetal lamb: differential development and change by oxygen and endotoxin. Br J Pharmacol 132:241–251CrossRefPubMedGoogle Scholar
  22. Collier AC, Ganley NA, Tingle MD et al (2002) UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol 63:409–419CrossRefPubMedGoogle Scholar
  23. Cresteil T (1998) Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 15(Suppl):45–51PubMedGoogle Scholar
  24. Creuwels LA, van Golde LM, Haagsman HP (1997) The pulmonary surfactant system: biochemical and clinical aspects. Lung 175:1–39PubMedGoogle Scholar
  25. De Morais S, Wilkinson G, Blaisdell J, Nakamura K, Meyer U, Goldstein J (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422PubMedGoogle Scholar
  26. Denison MS, Fisher JM, Whitlock JP Jr (1988) Inducible, receptor-dependent protein-DNA interactions at a dioxin-responsive transcriptional enhancer. Proc Natl Acad Sci USA 85:2528–2532PubMedGoogle Scholar
  27. Drukker A, Guignard JP (2002) Renal aspects of the term and preterm infant: a selective Update. Curr Opin Pediat 14:175–182Google Scholar
  28. Eiselt R, Domanski TL, Zibat A et al (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447–458CrossRefPubMedGoogle Scholar
  29. Floros J, Kala P (1998) Surfactant proteins: molecular genetics of neonatal pulmonary diseases. Annu Rev Physiol 60:365–384CrossRefPubMedGoogle Scholar
  30. Francke U, Foellmer BE (1989) The glucocorticoid receptor gene is in 5q31–q32. Genomics 4:610–612CrossRefPubMedGoogle Scholar
  31. Fromm MF (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54:1295–1310CrossRefPubMedGoogle Scholar
  32. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552–557PubMedGoogle Scholar
  33. Galanello R, Cipollina MD, Carboni G, Perseu L, Barella S, Corrias A, Cao A (1999) Hyperbilirubinemia, glucose-6-phosphate-dehydrogenase deficiency and Gilberf’s syndrome. Eur J Pediatr 158:914–916CrossRefPubMedGoogle Scholar
  34. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587CrossRefPubMedGoogle Scholar
  35. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I (2002) MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 54:610–616CrossRefPubMedGoogle Scholar
  36. Gonzales LW, Guttentag SH, Wade KC, Postle AD, Ballard PL (2002) Differentiation of human pulmonary type II cells in vitro by glucocorticoid plus cAMP. Am J Physiol Lung Cell Mol Physiol 283:L940–L951PubMedGoogle Scholar
  37. Goodwin B, Hodgson E, Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329–1339PubMedGoogle Scholar
  38. Gu L, Gonzales FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73–77PubMedGoogle Scholar
  39. Guignard JP, Drukker A (1999) Why do newborn infants have a high plasma creatinine? Pediatrics 103:49CrossRefGoogle Scholar
  40. Ha HR, Chen J, Krahenbuhl S, Follath F (1996) Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol 49:309–315CrossRefPubMedGoogle Scholar
  41. Hakkola J, Pelkonen O, Pasanen M, Raunio H (1998) Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 28:35–72CrossRefPubMedGoogle Scholar
  42. Hammerman C (1995) Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 22:457–479PubMedGoogle Scholar
  43. He Y, Crouch EC, Rust K, Spaite E, Brody SL (2000) Proximal promoter of the surfactant protein D gene: regulatory roles of AP-1, forkhead box, and GT box binding proteins. J Biol Chem 275:31051–31060PubMedGoogle Scholar
  44. Hollenberg SM, Weinberger C, Ong ES et al (1985) Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318:635–641CrossRefPubMedGoogle Scholar
  45. Hustert E, Haberl M, Burk O et al (2001a) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–779CrossRefPubMedGoogle Scholar
  46. Hustert E, Zibat A, Presecan-Siedel E et al (2001b) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454–1459PubMedGoogle Scholar
  47. Ingelman-Sundberg M (2001) Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482:11–19PubMedGoogle Scholar
  48. Iyer L, Das S, Janisch L et al (2002) UGTlAlα28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43–47CrossRefPubMedGoogle Scholar
  49. Jansen PL (1999) Diagnosis and management of Crigler-Najjar syndrome. Eur J Pediatr 158(Suppl 2):S89–S94PubMedGoogle Scholar
  50. Jobe AH, Newnham J, Willet K, Sly P, Ikegami M (1998) Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics 102:1116–1126CrossRefPubMedGoogle Scholar
  51. Johno I, Kuzuya T, Suzuki K et al (1988) Is free fraction measurement of phenytoin always necessary in pediatric epileptic patients? Ther Drug Monit 10:39–44PubMedGoogle Scholar
  52. Jones SA, Moore LB, Shenk JL et al (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39CrossRefPubMedGoogle Scholar
  53. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR (2000) Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 16: 297–306CrossRefPubMedGoogle Scholar
  54. Kaplan M, Hammerman C, Rubaltelli FF et al (2002) Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology 35:905–911CrossRefPubMedGoogle Scholar
  55. Kast HR, Goodwin B, Tarr PT et al (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908–2915CrossRefPubMedGoogle Scholar
  56. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–294PubMedGoogle Scholar
  57. Koch I, Weil R, Wolbold R et al (2002) Interindividual variability and tissue-specificity in the expression of cytochrome p450 3A mRNA. Drug Metab Dispos 30:1108–1114CrossRefPubMedGoogle Scholar
  58. Kuehl P, Zhang J, Lin Y et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391CrossRefPubMedGoogle Scholar
  59. Kwei GY, Alvaro RF, Chen Q et al (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581–587PubMedGoogle Scholar
  60. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T (1997) Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625–634CrossRefPubMedGoogle Scholar
  61. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar F (1994) Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer. Cancer Epidemiol Biomark Prev 3:675–682Google Scholar
  62. Langdown ML, Sugden MC (2001) Enhanced placental GLUT1 and GLUT3 expression in dexamethasone-induced fetal growth retardation. Mol Cell Endocrinol 185:109–117CrossRefPubMedGoogle Scholar
  63. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12:457–463CrossRefPubMedGoogle Scholar
  64. Liggins GC (1968) Premature parturition after infusion of corticotrophin or cortisol into foetal lambs. J Endocrinol 42:323–329PubMedGoogle Scholar
  65. Lin JH (2002) Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr Drug Metab 3:623–646CrossRefPubMedGoogle Scholar
  66. Linnemann K, May K, Zschiesche M, Siegmund W, Kroemer HK, Fusch C (2002) Transfer of talinolol in dually in vitro perfused human placentas: possible involvement of P-glycoprotein (P-gp). Eur J Pediatr 161Google Scholar
  67. Lupp A, Lau K, Trautmann AK, Krausse T, Klinger W (1999) Transplantation of fetal liver tissue Suspension into the spleens of adult syngenic rats: inducibility of cytochrome P450 dependent monooxygenase functions by beta-naphthoflavone, phenobarbital and dexamethasone. Exp Toxicol Pathol 51:65–74PubMedGoogle Scholar
  68. Lupp A, Danz M, Muller D, Klinger W (2002) Expression and inducibility of cytochrome P450 isoforms in 1-year-old intrasplenic liver cell transplants in rats. Transpl Int 15:96–107CrossRefPubMedGoogle Scholar
  69. Mason RJ, Greene K, Voelker DR (1998) Surfactant protein A and surfactant protein D in health and disease. Am J Physiol 275:L1–13PubMedGoogle Scholar
  70. McMurphy DM, Heymann MA, Rudolph AM, Melmon KL (1972) Developmental changes in constriction of the ductus arteriosus: responses to oxygen and vasoactive agents in the isolated ductus arteriosus of the fetal lamb. Pediatr Res 6:231–238PubMedGoogle Scholar
  71. Meistelman C, Saint-Maurice C, Lepaul M, Levron JC, Loose JP, Mac GK (1987) A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 66:13–16PubMedGoogle Scholar
  72. Michalets EL (1998) Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84–112PubMedGoogle Scholar
  73. Moe AJ (1995) Placental amino acid transport. Am J Physiol 268:C1321–C1331PubMedGoogle Scholar
  74. Moise KJ Jr, Huhta JC, Sharif DS, Ou CN, Kirshon B, Wasserstrum N, Cano L (1988) Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 319:327–331PubMedCrossRefGoogle Scholar
  75. Monaghan G, McLellan A, McGeehan A et al (1999) Gilberts syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. J Pediatr 134:441–446PubMedGoogle Scholar
  76. Moore LB, Goodwin B, Jones SA (2000) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–7502PubMedGoogle Scholar
  77. Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A (1990) Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem 191:437–444CrossRefPubMedGoogle Scholar
  78. Muglia LJ, Bae DS, Brown TT, Vogt SK, Alvarez JG, Sunday ME, Majzoub JA (1999) Proliferation and differentiation defects during lung development in corticotropin-releasing hormone-deficient mice. Am J Respir Cell Mol Biol 20:181–188PubMedGoogle Scholar
  79. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS, Boobis AR (1993) Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis 14:585–592PubMedGoogle Scholar
  80. Nakamura Y, Ikeda S, Furukawa T, Sumizawa T, Tani A, Akiyama S, Nagata Y (1997) Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys Res Commun 235:849–853PubMedGoogle Scholar
  81. Naltner A, Ghaffari M, Whitsett JA, Yan C (2000) Retinoic acid stimulation of the human surfactant protein B promoter is thyroid transcription factor 1 site-dependent. J Biol Chem 275:56–62CrossRefPubMedGoogle Scholar
  82. Oesterheld JR (1998) A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol 8:161–174PubMedGoogle Scholar
  83. Overmeire van B, Touw D, Schepens PJ, Kearns GL, van den Anker JN (2001) Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 70:336–343PubMedGoogle Scholar
  84. Painter MJ, Minnigh MB, Gaus L, Scher M, Brozanski B, Alvin J (1994) Neonatal phenobarbital and phenytoin binding profiles. J Clin Pharmacol 34:312–317PubMedGoogle Scholar
  85. Pokela ML, Olkkola KT, Seppala T, Koivisto M (1993) Agerelated morphine kinetics in infants. Dev Pharmacol Ther 20:26–34PubMedGoogle Scholar
  86. Puzianowska-Kuznicka M, Shi YB (1996) Nuclear factor I as a potential regulator during postembryonic organ development. J Biol Chem 271:6273–6282PubMedGoogle Scholar
  87. Rane A (1992) Drug disposition and action in infants and children. In: Yaffe SJ, Aranda JV (eds) Pediatric pharmacology. Saunders, Philadelphia, pp 10–21Google Scholar
  88. Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, Owens IS (1992) A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267:3257–3261PubMedGoogle Scholar
  89. Rust K, Bingle L, Mariencheck W, Persson A, Crouch EC (1996) Characterization of the human surfactant protein D promoter: transcriptional regulation of SP-D gene expression by glucocorticoids. Am J Respir Cell Mol Biol 14:121–130PubMedGoogle Scholar
  90. Rylance G (1991) Pharmacological principles and kinetics. In: Rylance G, Harvey D, Aranda JV (eds) Neonatal clinical pharmacology and therapeutics. Butterworth-Heinemann, Oxford, pp 1–25Google Scholar
  91. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295PubMedGoogle Scholar
  92. Saito T, Takahashi Y, Hashimoto H, Kamataki T (2001) Novel transcriptional regulation of the human CYP3A7 gene by Spl and Sp3 through nuclear factor kappa B-like element. J Biol Chem 276:38010–38022PubMedGoogle Scholar
  93. Schaeffeler E, Lang T, Zanger UM, Eichelbaum M, Schwab M (2001) High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem 47:548–555PubMedGoogle Scholar
  94. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524PubMedGoogle Scholar
  95. Schuetz JD, Beach DL, Guzelian PS (1994) Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11–20PubMedGoogle Scholar
  96. Schwab M, Schaffeler E, Marx C et al (2002) Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12:429–436CrossRefPubMedGoogle Scholar
  97. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3:239–249PubMedGoogle Scholar
  98. Siegmund W, Ludwig K, Giessmann T et al (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572–583PubMedGoogle Scholar
  99. Smith GC (1998) The pharmacology of the ductus arteriosus. Pharmacol Rev 50:35–58PubMedGoogle Scholar
  100. Sonnier M, Cresteil T (1998) Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251:893–898CrossRefPubMedGoogle Scholar
  101. St Pierre MV, Serrano MA, Macias RI et al (2000) Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279:R1495–R1503PubMedGoogle Scholar
  102. St Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T (2002) Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 87:1856–1863PubMedGoogle Scholar
  103. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP (2002) Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259–265PubMedGoogle Scholar
  104. Sueyoshi T, Negishi M (2001) Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41:123–143CrossRefPubMedGoogle Scholar
  105. Tanabe M, Ieiri I, Nagata N et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-l gene. J Pharmacol Exp Ther 297:1137–1143PubMedGoogle Scholar
  106. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K (1999) CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 66:528–534PubMedCrossRefGoogle Scholar
  107. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T (1991) Expression of CYP2D6 in developing human liver. Eur J Biochem 202:583–588CrossRefPubMedGoogle Scholar
  108. Treluyer JM, Benech H, Colin I, Pruvost A, Cheron G, Creseil T (2000) Ontogenesis of CYP2C-dependent arachidonic acid metabolism in the human liver: relationship with sudden infant death syndrome. Pediatr Res 47:677–683PubMedGoogle Scholar
  109. Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616CrossRefPubMedGoogle Scholar
  110. Ugele B, St Pierre MV, Pihusch M, Bahn A, Hantschmann P (2003) Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab 284:E390–E398PubMedGoogle Scholar
  111. Velden van der VH (1998) Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm 7:229–237PubMedGoogle Scholar
  112. Watchko JF, Daood MJ, Mahmood B, Vats K, Hart C, Ahdab-Barmada M (2001) P-glycoprotein and bilirubin disposition. J Perinatol 21(Suppl 1):S43–S47PubMedGoogle Scholar
  113. Weinshilboum RM (1992) Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 22:1055–1071PubMedCrossRefGoogle Scholar
  114. Xie W, Yeuh MF, Radominska-Pandya A et al (2003) Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USAGoogle Scholar
  115. Yang HY, Lee QP, Rettie AE, Juchau MR (1994) Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol 46:922–928PubMedGoogle Scholar
  116. Zamora S, Benador N, Lacourt G, Girardin E (1995) Renal handling of carnitine in ill preterm and term neonates. J Pediatr 127:975–978PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Ingolf Cascorbi
    • 1
  • Knud Linnemann
    • 2
  1. 1.Institut für PharmakologieUniversitätsklinikum Schleswig-Holstein, Campus KielKiel
  2. 2.Institut für Pharmakologie, Abteilung Neonatologie der Klinik für Kinder- und JugendmedizinErnst-Moritz-Arndt-UniversitätGreifswald

Personalised recommendations